RUNX1 and cholangiocarcinoma: Consistent with RUNX1 expression patterns, significant overexpression of MUC13 was observed in various gastrointestinal cancers, such as cholangiocarcinoma, colon cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, rectal cancer, and gastric cancer (Figure 6A).